Health Care [ 9/12 ] | Biotechnology [ 47/73 ]
NASDAQ | Common Stock
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases.
It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain.
The company was incorporated in 2022 and is based in New York, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 12, 25 | -0.73 | - |
| Mar 26, 25 | -0.50 | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 0.00 - | -76.59 M - | Decreased by N/A% - |
| Dec 31, 24 | 0.00 - | -52.87 M - | Decreased by N/A% - |
| Mar 31, 24 | 0.00 - | -19.88 M - | Decreased by N/A% - |
| Dec 31, 23 | 0.00 - | -11.87 M - | Decreased by N/A% - |